<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1F9B0EB9-CEEC-4F67-83CF-CFB00F90EF31"><gtr:id>1F9B0EB9-CEEC-4F67-83CF-CFB00F90EF31</gtr:id><gtr:firstName>Gebhard</gtr:firstName><gtr:otherNames>Franz</gtr:otherNames><gtr:surname>Schertler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105178937"><gtr:id>E09CECE0-26E8-4F5C-96AE-F41F4A009C2A</gtr:id><gtr:title>GPCR Signalling: Rhodopsin and beta-adrenergic receptor structure</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105178937</gtr:grantReference><gtr:abstractText>G protein-coupled receptors comprise the largest gene family in the human genome. They are central to neurobiology, pharmacology and sensory physiology. The visual system is by far the best-studies system at the molecular level and at the level of brain organisation. Working at the molecular level, we have determined the structure of rhodopsin by X-ray crystallography and electron microscopy. Using microcrystallography we have solved the structure of a beta 1 adrenergic receptor and human beta 2 adrenergic receptor. These receptors are pharmocologically very important targets for beta blockers.||The most important question left in the field is the molecular mechanism of G protein-coupled receptor activation. For this we will need the structure of the activated receptor in complex with other signalling molecules. We will therefore, develop biochemical protocols to isolate rhodopsin/transducin, rhodopsin/rhodopsin kinase, and rhodopsin/arrestin complexes using native and recombinant proteins and will crystallise these signalling complexes. In contrast to other systems, the components of the visual system are well characterised and available from native sources as well as expression systems. We will crystallise the signalling complexes and solve their structure with the most advanced X-ray and electron microscopy techniques available. From these structures we will gain insight into the general activation mechanism of G protein-coupled receptors. This mechanism is of crucial importance for the regulation of neurobiological processes and it might give new possibilities for pharmacological intervention.</gtr:abstractText><gtr:technicalSummary>Activation of a G protein-coupled receptor initiates two biochemical cascades, one leading to amplification of the cellular signal and the other to desensitization and quenching of the signal. Binding and activation of G protein and receptor kinase and specific recognition of the activated receptor surface are the first events in the two cascades. Competition between the G protein and the receptor kinase for the activated receptor surface are central to the progression of the two cascades. Binding of arrestin to phosphorylated rhodopsin then terminates the signal. The most direct insight into this process can be gained by crystallising the signalling complexes. The signalling components are best characterised in the visual system and in the adrenergic receptor signalling pathway. Recombinant rhodopsin and adrenergic receptors are expressed and purified in our laboratory, and we have experience in the crystallisation of rhodopsin and adrenergic receptors. Recently we solved structures of a beta 2 and a beta 1 adrenergic receptor with an antagonist bound. Now we are working on the structure of the signalling complexes.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2688154</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heptares Therapeutics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The implications of the adregnergic receptor structures</gtr:description><gtr:id>7130CB10-2346-4E58-A67E-2D8C1CF2E896</gtr:id><gtr:impact>Member of scientific advisory board and a consultant</gtr:impact><gtr:outcomeId>E351F825843-1</gtr:outcomeId><gtr:partnerContribution>Member of the scientific advisory board of Heptares and a consultant</gtr:partnerContribution><gtr:piContribution>The structure of a stabilised adrenergic receptor played a crucial role in the formation of the biotech spin out company Heptares</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>219695</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HFSP Grant</gtr:description><gtr:end>2009-05-02</gtr:end><gtr:fundingOrg>Human Frontier Science Program (HFSP)</gtr:fundingOrg><gtr:id>7D327655-5AFA-45BF-8A3F-FB3C62159E91</gtr:id><gtr:outcomeId>K8g6WayojYv0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EMBO Long-term Fellowship</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>European Molecular Biology Organisation</gtr:fundingOrg><gtr:id>5F30664C-3B38-48F1-BD1A-8921BD688EB9</gtr:id><gtr:outcomeId>4FEA2B87B3F0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73220</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Grant</gtr:description><gtr:end>2008-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>187740A4-6573-4226-880A-1318B7F8E6A3</gtr:id><gtr:outcomeId>2197810E7BE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>399641</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC FP6 Grant</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>F25C0E6C-0E4C-47A6-B40D-1B280515F8AB</gtr:id><gtr:outcomeId>2FD1B01E5890</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>364405</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A3C645F6-BC2C-42D2-A70F-E4AA1C96A01E</gtr:id><gtr:outcomeId>7CA942ABFC90</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158856</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC Marie Curie Fellowship</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>4541255C-49A9-46D4-BEDF-A4F53D0829C2</gtr:id><gtr:outcomeId>664D9733C030</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Crystal structure of beta 2 adregenic receptor</gtr:description><gtr:grantRef>MC_U105178937</gtr:grantRef><gtr:id>8BD9B3F7-A5C1-4A08-8FB6-06266FFB936F</gtr:id><gtr:impact>Crystal structure of human beta 2 adrenergic receptor</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>B7A4FA472A3</gtr:outcomeId><gtr:patentId>WO2009038755</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Crystal structure of beta 2 adregenic receptor</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A 96 well sandwich plate for lipidic cubic phase (LCP) was developed. The setup is UV transparent and crystals grown in the mesophase can easily be harvested. The plate was tested with bacteriorhodropsin LCP cystallisations. We need to work on a small scale because our receptors and signalling complexes can only be isolated in small amounts</gtr:description><gtr:grantRef>MC_U105178937</gtr:grantRef><gtr:id>53AF4C35-7D6D-4FCA-A0EE-4BBBDB9CF8FA</gtr:id><gtr:impact>Lipidic Cubic Phase Plate</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>B79AF5C2507</gtr:outcomeId><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Lipidic Cubic Phase (LCP)</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Non protein crystals can be identified easily by their UV absorption properties. This was very helpful in the large scale screen for the beta 1 adrenergic reception where 16500 crystallisation attempts were analysed with the system.</gtr:description><gtr:id>340E87F3-F014-488F-9EC8-091C34EDB034</gtr:id><gtr:impact>The instrument is now available to all users at MRC LMB</gtr:impact><gtr:outcomeId>B144850C3F9</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>A multi wavelength 96 well optical imaging system</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>UV microscope to identify protein crystals</gtr:description><gtr:id>72C5F077-68FA-474D-AC45-BFFD1A9043AD</gtr:id><gtr:impact>identification of beta adrenergic receptor crystals</gtr:impact><gtr:outcomeId>6AE66F8F005</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UV Microscope to identify protein crystals</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Heptares Therapeutics Ltd</gtr:companyName><gtr:description>Heptares is a drug development company that uses knowledge about the structure and function of G protein coupled receptors (GPCRs) to develop better drugs. The input from LMB consisted of know-how and patents that allow GPCRs to me modified to allow crystallisation and structure analysis of the structure in complex with potential new drugs.; www.heptares.com</gtr:description><gtr:id>817BCB0B-8DB1-48AE-9CD1-546D4B196E5A</gtr:id><gtr:impact>The people employed have very valuable knowledge and experience of GPCR pharmacology, so we gain from this while in exchange acting as consultants. MRC also have 600,000 shares in Heptares.</gtr:impact><gtr:outcomeId>E073EC506FB</gtr:outcomeId><gtr:url>http://www.heptares.com/</gtr:url><gtr:yearCompanyFormed>2007</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>4353EC1C-1064-4D62-A83C-43388921B882</gtr:id><gtr:title>Protein crystallography with a micrometre-sized synchrotron-radiation beam.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f325ee2468867aaaec862512de7aa85c"><gtr:id>f325ee2468867aaaec862512de7aa85c</gtr:id><gtr:otherNames>Moukhametzianov R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>2AEA4352676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7C530AB-4B19-41B5-ADC5-48B16BAD47EF</gtr:id><gtr:title>Crystal structure of plant light-harvesting complex shows the active, energy-transmitting state.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2df0292891798649905f9614fd7e424"><gtr:id>c2df0292891798649905f9614fd7e424</gtr:id><gtr:otherNames>Barros T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>241E92F8881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9783C0B0-0CC3-4DC3-AF69-5EBCC70D58A2</gtr:id><gtr:title>Opsin stability and folding: modulation by phospholipid bicelles.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd726f4fd50452a74f35fc558f1ef06d"><gtr:id>cd726f4fd50452a74f35fc558f1ef06d</gtr:id><gtr:otherNames>McKibbin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>7AF88D5BBF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AC58A05-75B7-4D4D-847F-1C51E1EE0FA1</gtr:id><gtr:title>Recoverin binds exclusively to an amphipathic peptide at the N terminus of rhodopsin kinase, inhibiting rhodopsin phosphorylation without affecting catalytic activity of the kinase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00a35440865316f9d7e1996ff13fd008"><gtr:id>00a35440865316f9d7e1996ff13fd008</gtr:id><gtr:otherNames>Higgins MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>A93F5BDD7A7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4C29913-B697-493E-8205-43E6283FCBD2</gtr:id><gtr:title>Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc19d3a6f87f382a3d515169c6b38e2"><gtr:id>5cc19d3a6f87f382a3d515169c6b38e2</gtr:id><gtr:otherNames>Rasmussen SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>CAD276DE40C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27FBC177-EF43-4D1E-ABF2-75DC3F9CB81D</gtr:id><gtr:title>Signal transduction: the rhodopsin story continued.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e17be06663ff7481cc493f45ef4b978"><gtr:id>9e17be06663ff7481cc493f45ef4b978</gtr:id><gtr:otherNames>Schertler GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>6F7E4FF4B6D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE6ACB6A-A2EC-4279-90A2-D23D32A47BFE</gtr:id><gtr:title>Engineering G protein-coupled receptors to facilitate their structure determination.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3d1bb467c9a9b6b1af4649dc5d94ea9"><gtr:id>a3d1bb467c9a9b6b1af4649dc5d94ea9</gtr:id><gtr:otherNames>Tate CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>1DC3AEEBF85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB95D44-BBD3-4E1C-9752-B50E9D051BF1</gtr:id><gtr:title>Rhodopsin photointermediates in two-dimensional crystals at physiological temperatures.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2920e07db3926ff17468f01d70b71c1"><gtr:id>c2920e07db3926ff17468f01d70b71c1</gtr:id><gtr:otherNames>Szundi I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>5798B071BE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>739C8A08-FB9C-420D-8E7C-0393E8767D81</gtr:id><gtr:title>Structural impact of the E113Q counterion mutation on the activation and deactivation pathways of the G protein-coupled receptor rhodopsin.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b8f3f4fca4094abb8345e7b487dc85"><gtr:id>42b8f3f4fca4094abb8345e7b487dc85</gtr:id><gtr:otherNames>Standfuss J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>B43D4F58CB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D4C441A-8E29-442B-91F8-A155F4518B43</gtr:id><gtr:title>Opsin stability and folding: the role of Cys185 and abnormal disulfide bond formation in the intradiscal domain.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd726f4fd50452a74f35fc558f1ef06d"><gtr:id>cd726f4fd50452a74f35fc558f1ef06d</gtr:id><gtr:otherNames>McKibbin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>364D19A3F3F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52CCE4F8-9A95-437F-941C-D5A58CF9E32D</gtr:id><gtr:title>The structural basis of agonist-induced activation in constitutively active rhodopsin.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b8f3f4fca4094abb8345e7b487dc85"><gtr:id>42b8f3f4fca4094abb8345e7b487dc85</gtr:id><gtr:otherNames>Standfuss J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>jd7pigmH27A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9F0D209-C4EA-4F92-A0BB-6E5FF90AF8EF</gtr:id><gtr:title>New G-protein-coupled receptor crystal structures: insights and limitations.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4606692b5613a60589d5e5657f35ac53"><gtr:id>4606692b5613a60589d5e5657f35ac53</gtr:id><gtr:otherNames>Kobilka B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>84BE0325D7F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>732A13B3-FC6C-4C58-8770-A72AAE59AC32</gtr:id><gtr:title>Development and crystallization of a minimal thermostabilised G protein-coupled receptor.</gtr:title><gtr:parentPublicationTitle>Protein expression and purification</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e358d7ed8ed9d826b3972c81abba6b"><gtr:id>16e358d7ed8ed9d826b3972c81abba6b</gtr:id><gtr:otherNames>Warne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1046-5928</gtr:issn><gtr:outcomeId>D07AE0D7A5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35CBB699-3D1D-4A23-9AD9-AD8801D35A1B</gtr:id><gtr:title>Structure of a beta1-adrenergic G-protein-coupled receptor.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e358d7ed8ed9d826b3972c81abba6b"><gtr:id>16e358d7ed8ed9d826b3972c81abba6b</gtr:id><gtr:otherNames>Warne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>CB4B762D967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF93A3C5-568B-495D-A49C-FC5C2C1A6350</gtr:id><gtr:title>Crystal structure of a thermally stable rhodopsin mutant.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b8f3f4fca4094abb8345e7b487dc85"><gtr:id>42b8f3f4fca4094abb8345e7b487dc85</gtr:id><gtr:otherNames>Standfuss J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>3BA5938E9B5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105178937</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>